Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection

Shruti Shandilya a, Sandeep Kumar b,c, Niraj Kumar Jha d, Kavindra Kumar Kesari a,* Janne Ruokolainen a,*

a Department of Applied Physics, School of Science, Aalto University, Espoo, Finland
b Department of Biochemistry, International Institute of Veterinary Education and Research, Haryana, India
c Clinical Science, Targovox Oy, Saukonpaadenranta 2, Helsinki 00180, Finland
d Department of Biotechnology, School of Engineering and Technology (SET), Sharda University, Plot no. 32–34, Knowledge Park III, Greater Noida 201310, India

HIGHLIGHTS

• Owing to high O2 consumption, brain is highly vulnerable to oxidative stress.
• Gut-brain axis act as a vital pathway of communication and physiological regulation.
• Altered gut microbiota-mediated oxidative stress is associated with neurodegeneration.
• Healthy gut microbiota has an immense antioxidative and anti-inflammatory role.
• Antioxidative prebiotics and probiotics attenuates neurodegenerative symptoms.
• Current databases and in silico tools will help to develop new therapeutic regimens.

ABSTRACT

Background: Recent research on the implications of gut microbiota on brain functions has helped to gather important information on the relationship between them. Pathogenesis of neurological disorders is found to be associated with dysregulation of gut-brain axis. Some gut bacteria metabolites are found to be directly associated with the increase in reactive oxygen species levels, one of the most important risk factors of neurodegeneration. Besides their morbid association, gut bacteria metabolites are also found to play a significant role in reducing the onset of these life-threatening brain disorders.

Aim of Review: Studies done in the recent past raises two most important link between gut microbiota and the brain: “gut microbiota-oxidative stress-neurodegeneration” and gut microbiota-antioxidant-neuroprotection. This review aims to gives a deep insight to our readers, of the collective studies done, focusing on the gut microbiota mediated oxidative stress involved in neurodegeneration along with a focus on those studies showing the involvement of gut microbiota and their metabolites in neuroprotection.

Key Scientific Concepts of Review: This review is focused on three main key concepts. Firstly, the mounting evidences from clinical and preclinical arenas shows the influence of gut microbiota mediated oxidative stress.
Introduction

Enteric nervous system (ENS), also known as the second brain of the body acts as a key link in understanding the bidirectional communication between the gastrointestinal (GI) tract and the central nervous system (CNS) [1]. Enteric neurons communicate with the CNS via neuronal (vagus nerve), endocrine, and immune pathways, which are involved in maintaining gut health [2]. However, the modulating factor which can regulate this communication is gut microbiota. Among the gut microbial population (fungi, archaea, virus, bacteria and parasites), particularly gut bacteria constitute equal number to that of human cells in the body [3] and interestingly possess a metabolic potential equivalent to that of human liver [4]. Continuous research in this area shows the immense importance of gut microbiota not only in the functioning of the immune system [5] and regulatory metabolism [6] but even in the development of various organs [7]. Variable environmental factors such as diet [8], drugs [9] and host factors including age and genetics [10] not only alter the composition of gut microbiota but also can cause the change in signaling activity of them. Also, Immunoglobulin A (IgA), which is the most abundant antibody secreted at mucosal surface, coats the commensal bacteria in the gut and maintains diverse and stable gut microbiota community [11,12]. Even, gut microbiota is known to influence the serum protein zonulin, which is required to regulate intestinal and vascular endothelium (blood-brain barrier) tight junctions [13]. Changes in gut microbiota directly affect zonulin pathway resulting in leaky gut [13]. Moreover, gut microbiota is one of the contributing factors controlling gut peristalsis [14]. Among the endocrine factors, elevated levels of cortisol has been observed as contributing factors in gut dysbiosis and is considered a cause of stress and depression [15]. Thus, gut microbiota directly influences human health by sensing, modulating and circulating a vast number of chemical signals coming from the environment.

The relationship between intestinal bacteria and neurological diseases was first hypothesized by Elie Metchnikoff and colleagues in 1900s, which has now been recognized by many research groups. Neurodegenerative diseases (NDDs) were first believed to be caused by defects in the nervous system neglecting the facts that microorganisms in the gut possess the ability to produce and modify various immune, metabolic and neurochemical factors which are known to directly affect the nervous system [16]. NDDs are mainly caused by oxidative damage, increased reactive oxygen species (ROS) production, neuroinflammation and disruptive energy metabolism, which on the other hand also affects the gut microbial population [17]. Surprisingly, gut microbial composition alters with the changes in the metabolism of the body from healthy to diseased state [18,19]. This shows the intersection of gut microbiota between the host and the environment, and its morbidity association with various neurological and psychological disorders. Gut dysbiosis and neuroinflammation are consistent factors in the pathophysiology of various neurological disorders. In this review, we emphasize showcasing the role gut microbiota-mediated oxidative stress in neurodegeneration, including the explanation of mechanisms of ROS production, why the brain is more susceptible to oxidative stress and how gut microbial metabolites influence the oxidative stress-induced damage in the brain with a focus on Alzheimer’s disease (AD), Parkinson’s disease (PD) and Traumatic brain injury (TBI).

Despite the role of gut microbiota in the pathogenesis of NDDs, unsurprisingly, gut microbiota also has the potential to protect the brain from damage either by releasing the metabolites generated by them from converting dietary fibers, polyphenols or host molecules like bile acids and steroid hormones or their composition in the gut can be modulated by prebiotics in order to promote neuro resilience [20]. Neuroprotective role of gut microbiota is well documented in recent studies, it was observed that Lactobacillus buchneri KU200793 isolated from Korean fermented food showed higher antioxidant activity and was able to protect the SH-SYSY cells from 1-methyl-4-phenylpyridinium (MPP+), suggesting its probiotic and neuroprotective effects [21]. Similarly, it was reported that exopolysaccharides isolated from Lactobacillus delbrueckii sps. bulgaricus B3 and Lactobacillus plantarum CD2 protected SH-SYSY cells from Aβ(1–42)-induced apoptosis [22], which potentiates their role as a promising natural chemical constituent for the pharmacological therapy of AD. Moreover, treatment of SH-SYSY and mouse model with heat-killed strain of Ruminococcus albus showed the neuroprotective effects, it was found to be very effective in reducing ROS levels and increasing superoxide dismutase (SOD) and glutathione (GSH) levels in hydrogen peroxide (H2O2) treated SH-SYSY cells and in sodium arsenate treated animal models [23]. Likewise, anti-Alzheimer’s actions of Lactobacillus plantarum MTCC1325 have been studied in Albino rats with AD induced by D-Galactose (D-Gal) [24]. It has been shown that the L. plantarum protects against memory deficit in D-Gal and scopolamine-induced AD in mice [25]. Taken together, these studies reflect the promising role of gut microbiota, their antioxidative and subsequently, their neuroprotective roles. Based on these foundational discoveries, we describe the role of gut microbiota, their metabolites, along with anti-inflammatory and antioxidative probiotics in neuroprotection. Also, we have gathered information about the databases and in silico strategies utilized to study gut-brain interactions. Altogether, this review will give a deep insight into the dual role of gut microbiota in oxidative stress-induced neurodegeneration and gut microbial metabolites-mediated antioxidative mechanism-based neuroprotection.

ROS and oxidative stress

Oxidative stress corresponds to the disruption of redox signaling pathway in cells due to an increase of ROS level more than that of antioxidant levels. This state of imbalance results in deleterious effects and is a leading cause of many neurological diseases. Every chemical reaction involved in aerobic metabolism results in the
formation of reactive intermediate products which are unstable and short-lived, known as ROS [26,27].

Biomolecular oxygen ($O_2$) possesses two unpaired electrons which cannot be reduced completely, thus its incomplete reduction results in the formation of highly electrophilic and short-lived ROS like $H_2O_2$, superoxide anion, nitric oxide, peroxynitrite anion, hydroxyl and peroxyl radicals [28]. Either ROS is generated as an intermediate in normal cellular processes via ROS generating enzymes or in the presence of exogenous factors like drugs, toxins, and radiations [29]. Neuronal tissues due to their high metabolic rate produces a large amount of ROS in comparison to the other organs. Mitochondria is considered as the main cellular site of ROS generation in brain, where during the process of ATP generation (mitochondrial oxidative phosphorylation), anion superoxide is generated as a byproduct, which is then rapidly transformed into $H_2O_2$ and $O_2$ by SOD [30]. The greater the amount of $O_2$, the greater is the formation of superoxide, which further results in more ROS like $H_2O_2$ and hydroxyl radicals due to the addition of electrons from leaky electron transport chain (ETC) (complex I and III) [31]. Mitochondrial ROS production also indicates neuronal activity, as intense synaptic transmission boosts (ETC) (complex I and III) [31]. Mitochondrial ROS production also indicates neuronal activity, as intense synaptic transmission boosts superoxide production [32]. Though on one hand mitochondrial ROS can be regulated by intracellular calcium ($Ca^{2+}$) levels [33], moreover, increased mitochondrial ROS production is also associated with the increased mitochondrial membrane potential. Besides inner mitochondrial membrane, mitochondrial matrix enzyme, aconitase also contributes to ROS production by transforming $H_2O_2$ into hydroxyl radicals facilitated by iron-sulphur cluster in Fenton reaction. Many other enzymes like external NADH dehydrogenase, proline dehydrogenase, dihydroorotate dehydrogenase, and aconitase also contribute to ROS production by transforming $H_2O_2$ into hydroxyl radicals facilitated by iron-sulphur cluster in Fenton reaction.

Besides inner mitochondrial membrane, monoamine oxidases (MAO) present in outer mitochondrial membrane, present in most of the cell types including neurons and is among the primary source of ROS. MAO catalyzes the oxidative deamination of monoamines, requiring cofactor FAD (flavin adenine dinucleotide), by utilizing molecular $O_2$ to remove an amine group from the molecule, where $H_2O_2$ is produced as a byproduct of the reaction [35]. The two isoforms of MAO, namely MAO-A and MAO-B have been known to regulate the redox state of glia and neuronal cells. MAO-A is mainly found in the catecholaminergic neurons and is involved in oxidation of noradrenaline and serotonin, whereas MAO-B is particularly expressed in serotonergic neurons and glial cells and oxidizes β-phenylethylamine [36]. Thirdly, an isoform of nitric oxide synthase (NOS) nNOS present in neurons is also one of the sources of ROS in brain, which is regulated by $Ca^{2+}$ binding protein calmodulin. NOS catalyzes the oxidation of L-arginine to L-citrulline, producing nitric oxide (NO), utilizing NADPH, tetrahydrobiopterin and $O_2$ as a cofactor [37]. Though on one hand NO acts as a critical signaling molecule which regulates synaptic transmission, but is also capable of interfering the redox homeostasis by interacting with superoxides to form highly reactive peroxynitrite compounds, which are directly involved in causing nitrosative stress in cells and is associated with apoptotic and necrotic cell death at low concentration and high concentrations, respectively [37].

Besides other enzymes, one of the major endogenous sources of ROS in brain during physiological conditions includes NADPH oxidases (NOX) which catalyze the oxidation of NADPH producing superoxide as its main product. Though, NOX are found to be primarily located in plasma membrane and phagosomes of polymorphonuclear neutrophils, previous immunohistology assessments of mouse and rat tissues showed its abundance in cortex and hippocampus regions of brain [38,39]. $Ca^{2+}$ acts as a prime activator of NOX, leading to the post synaptic localization of the enzyme complex in neurons, thus showing the involvement of NOX in neuronal activity [40]. Seven paralogs of NOX have been reported, namely NOX (1–5), dual oxidase DUOX (1 and 2), which differ in their size and domain structure but are mainly involved in ROS generation. The proteins get activated, undergo maturation, stabilization and translocation across the membrane on interaction with the other proteins, like NOX (1–3) gets activated by interacting with p22 (phox) transmembrane protein along with G-protein Rac. Similarly, NOX-4 gets activated by interacting with only p22 (phox) transmembrane protein, whereas NOX-5 and DUOX (1 and 2) gets activated by direct binding to $Ca^{2+}$. Upon activation NOX (1–3) and NOX-5 mainly catalyzes the production of superoxide and NOX-4, DUOX (1 and 2) are involved in the direct production of $H_2O_2$ [41]. NOX paralogs are found to be widely distributed in cortex, hippocampus and cerebellum in brain, most prominently NOX-2, NOX-3 and NOX-4. Previous reports also revealed the synergistic relation between mitochondrial ROS and NOX-ROS, thus supporting each other’s ROS generation [42]. To date, studies reveal a pivotal role of NOX in mediating the progression of chronic CNS diseases like AD, PD, amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD) [41]. Thus, development of isoform selective NOX inhibitor can be a promising therapeutic approach for the treatment of acute and chronic CNS disorders.

Within the cytoplasm, non-heme iron enzymes such as lipoxygenases catalyze the peroxidation of arachidonic acid in the presence of molecular $O_2$ and generate superoxide and hydroxyl radicals [43]. Many other enzymes in the cytoplasm like xanthine oxidase, cytochrome P450 monooxygenase, cyclooxygenase, D-amino oxidase are also important ROS producers [44]. In concert with mitochondria, organelles like peroxisomes are also the site of ROS production, where beta-oxidation of fatty acids catalyzed by glycolate oxidase and xanthine oxidase results in superoxide and $H_2O_2$ [27]. Also, increased ROS production occurs in endoplasmic reticulum due to unfolded protein response (UPR) [45].

Oxidative stress results in cellular damage by mediating three main reactions namely lipid peroxidation, oxidation of proteins and nucleic acid damage [46]. In fact, oxidative stress is considered as a part of the normal physiological process during aging, but have been known to be involved in chronic disorders of the brain like AD, PD, HD, ischemic stroke, depression and sclerosis [46]. Moreover, it plays a significant role in lifestyle-related metabolic disorders like Type 2 diabetes (T2D), non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, cardiovascular diseases and cancer [47].

Role of ROS in brain under physiological condition

Though ROS at higher levels is considered harmful causing biomolecular damage resulting in a wide range of cellular dysfunctions, whereas at a safe steady level ROS play a useful biological role. Under normal physiological conditions, extracellular ROS helps in mitigating infections by eliciting innate immunity responses. On the other hand, free radicals produced intracellularly helps to stimulate signaling pathways, apoptosis and defense system against oxidative stress. ROS also plays an important role in activating nuclear transcription factor NF-kB, which triggers inflammation leading to oxidative stress. Free radicals like hypochlorous acid (HOCl) are produced in lysosomes by the action of myeloperoxidases, which is used as a strong oxidative agent against pathogens. Thus, ROS act as a strong participant in signal transduction pathways regulating intracellular signaling [27,44].

With respect to CNS, ROS produced as a byproduct in many reactions under the physiological condition not only helps in modulating intracellular signal transduction pathways but also regulates cell proliferation, differentiation, and maturation [48]. Previous reports showed that ROS production and redox balance helps in mediating neuronal differentiation from precursor...
neuronal progenitor cells and the axon formation [49], also, it helps in neuronal cell expansion in their niches [50]. Moreover, It has been observed that redox signaling (ROS and oxidative states) also regulates the functioning of transcription factors like (NF-kB), nuclear factor of activated T-cells and the activator protein 1 (AP-1) along with the redox state of tyrosine phosphorylated protein PKC, thus plays an important role in influencing signaling cascades involved in neurogenesis [51]. Also, ROS like H$_2$O$_2$ have been observed to modulate the excitability of cortical neurons by enhancing the intracellular Ca$^{2+}$-signaling [52]. In a similar study it was observed that H$_2$O$_2$ increases the phosphorylation of ERK and cAMP-response element-binding protein (CREB) in cortical neurons and PC12 cells [53,54]. This shows that ROS plays a crucial role in influencing signaling cascades in nervous system and can act as a messenger in the signal transduction pathways.

ROS acts as a secondary messenger in various parts of the brain like hippocampus, cerebral cortex, hypothalamus, amygdala and spinal cord, thus helps in maintaining synaptic plasticity [55]. ROS was also found to be necessary for the long term potentiation (LTP) in the hippocampus, which is associated with learning and memory in mammals, thus, showing the involvement of ROS in synaptic enhancement [56,57]. ROS also affects the pain related behavior by its involvement in increasing the excitability of the central nucleus of amygdala, a region of brain responsible for emotional aspect of pain modulation [58]. Likewise, in spinal cord, neuroplasticity processes related to neuropathic and inflammatory pain is also controlled by ROS acting as a signaling molecule [59]. Reports from animal studies showed that NOX mediated direct production of ROS act as an important physiological process which helps in maintaining synaptic plasticity mechanisms particularly in hippocampus and visual cortex [60]. Moreover, dose dependent effect of H$_2$O$_2$, was observed to be an obligatory process to bring the redox changes and thus regulating synaptic plasticity [61].

Why brain is vulnerable to oxidative stress?

Approximately 20% of the basal O$_2$ is consumed by brain to support the ATP driven activity of ~ 86 billion neurons connected by trillions of synapses, supported by 250–300 billion glia [62]. It was reported that neurons (~1.9 million) and synapses (~14 million) begin to perish every minute when brain is deprived of O$_2$ [63]. Though O$_2$ is essential for the brain functioning, but ambiguity always lies in the fact that how oxidative stress causes neurodegeneration. O$_2$ derived free radical and non-radical species produced during redox signaling equally sustain brain health depicting its potential positive functionality [64]. It has been reported that O$_2$ and H$_2$O$_2$ produced by the action of NADPH oxidase (NOX-2) are involved in maintaining the growth of neuronal progenitor cells via PI3K/AKT pathway [49], also deletion of NOX-2 shows its importance in regulating cognitive functions of brain [65]. Recently, it is reported that NOX-2 derived H$_2$O$_2$ acts as an endogenous chemo-attractant supporting axonal path finding as well in its regeneration [66]. Thus, diverse reactive species are used by brain to perform signaling functions which make it more susceptible to oxidative stress. There are many other biochemical events which make the brain more vulnerable to oxidative stress that includes:

- a) Ca$^{2+}$ transients during action potential are required to maintain the bidirectional synaptic plasticity. When high Ca$^{2+}$ transients across the membrane are disrupted, the free intracellular Ca$^{2+}$ concentration increases, which then activates neuronal NOS (production of NO$_2$), phospholipase A2 and calpins damaging cytoskeleton. High NO also binds to cytochrome C oxidase, inhibiting mitochondrial respiration. Further, NO$^\cdot$ reacts with O$_2$ (from dysfunctional mitochondria) to form ONOO$^-$, Ca$^{2+}$ overloads in mitochondria abolishes the ATP generation by mediating efflux of Ca$^{2+}$/H$_2$O$_2$ via mitochondrial permeability transition pore (mPTP), this leads to necroptosis. Thus, disruption of Ca$^{2+}$ homeostasis makes brain susceptible to oxidative stress [67,68].

- b) Glutamate act as an excitotoxic amino acid for neurons and when taken in large amounts, it damages the cell by necrosis. This damage results in the release of large amount of glutamate in the extracellular environment, which also binds to receptors on adjacent neurons leading to a sustained release of Ca$^{2+}$and Na$^+$ in the cell. Reactive species like ONOO$^-$ inhibits the conversion of glutamate to glutamine by inactivating glutamine synthetase. Also, glutamate inhibits the exchange for intracellular glutamate for intracellular cysteine via X$^-$ transporters, resulting in depletion of GSH, which in turn leads to ferroptosis mediated death of neurons [69,70].

- c) Brain is enriched with redox transition metal ions like Fe$^{2+}$ and Cu$^{2+}$ which act as cofactors for many enzymes. Stress factors causing brain damage release metal ions capable of catalyzing free radical reactions. Moreover, the iron released have a prolonged existence because cerebrospinal fluid (CSF) has little or no iron binding capacity [71,72].

- d) Neurotransmitters like dopamine, serotonin and noradrenaline undergo auto-oxidation to generate ROS. Briefly, dopamine reacts with O$_2$ to produce semiquinone and O$_2$ which further reacts with O$_2$ to generate quinone. Quinone so produced is re-oxidized by O$_2$ to quinol and H$_2$O$_2$, where Mn$^{2+}$ reacts with H$_2$O$_2$ to produce OH$. Such auto-oxidation results in mitochondrial and lysosomal dysfunction [73,74].

- e) Brain is also sensitive to oxidative stress induced by glucose. To utilize most of the glucose for pentose phosphate pathway, neurons dephosphorylate fructosekinase, a rate-limiting glycolytic enzyme. The absence of glycolytic rate results in protein glycation and the formation of advanced glycation end products (AGE). AGE impairs proteins and mitochondrial function by inflammation-induced oxidative stress [75-77].

- f) Brain possesses a high content of polyunsaturated fatty acids particularly docosahexaenoic acid (DHA), which makes it more prone to oxidative stress because of lipid peroxidation and using peroxido lipids by brain to signal. Products of lipid peroxidation like 4-Hydroxynonenal inactivates glutamate transporters by increasing Ca$^{2+}$ levels, thus are neurotoxic. Lipids peroxides also inactivate alpha-ketoglutarate dehydrogenase, act as vasoconstrictive agent, damages protease, and is found to be a consistent factor in NDDs like AD [78,79].

- g) Microglia, the resident immune cells of the brain are important for brain development and function, but during the normal activity of phagocytosis, it produces O$_2$ and other reactive species. Active microglia produce O$_2$ via NOX-2. Thus, microglia activity depends on the total O$_2$ bioavailability and depicting damage to synapse by consuming more O$_2$ to produce O$_2$. Reactive species like H$_2$O$_2$ and NO$^\cdot$ attracts microglia at the site to enforce local inflammation driving neurodegeneration [80].

- h) Brain is prone to disrupted redox homeostasis due to modest antioxidant defense system in comparison to other tissues. Catalase content in neurons is much lower (50 times) than that of hepatocytes. Moreover, their presence in peroxisomes restricts its activity to act on H$_2$O$_2$ produced in other subcellular compartments. Similarly, neurons possess very low levels of GSH, which makes them sensitive to ferroptosis and resist them to metabolize electrophiles [81-83].
i) Hemoglobin is considered as neurotoxic for the brain when its reaction with excess of $\text{H}_2\text{O}_2$ results in the release of prooxidant iron ions and heme. Free heme is the strongest promoter of lipid peroxidation. Moreover, its binding with NO leads to vasoconstriction [84, 85].

j) Though brain contains low levels of cytochromes P450 enzyme, CYP2E1 that makes brain prone to oxidative stress due to leakage of electrons while catalyzing reactions. Study showed that its level might increase due to the consumption of ethanol and smoking [86].

k) DNA repair enzymes like poly-ADP-ribose polymerase (PARP-1), repairs DNA damage by cleaving NAD$^+$ and binding ADP ribose to nuclear proteins. But, overactivation of this enzyme leads to depletion of neuroprotective NAD$, restricting energy production and opening of transient receptor potential melastatin (TRPM2) $\text{Ca}^{2+}$ channels that results in neuronal cell death [87].

l) Being single-stranded and non-protected by histone proteins, RNA is more vulnerable to oxidation. Oxidized RNA halts the protein synthesis by ribosomes and might result in unfolded, truncated proteins if left unrepaired. It was reported that oxidized RNA along with redox-active transition metals catalyzes Fenton's reaction. It was also reported that oxidized Cu/Zn-SOD mRNA is a preclinical sign of ALS. However, there is a need to investigate its potent role in neurodegeneration [88].

**Gut microbiota, oxidative stress and neurodegeneration**

**Gut-brain axis under physiological condition**

Gastrointestinal (GI) tract encompasses trillions of commensal microorganisms and ~1000 of its species which plays an important role in preserving membrane barrier functions [2]. These microorganisms are permanent residents of small intestine and colon, involving the constant flux of molecules within the host organisms, thus regulating a variety of metabolic functions [58]. The microbial community gets stabilized in the host GI tract within two years after birth, but their composition varies among individuals and can change depending upon external factors like age, health, genetics and lifestyle [89]. Luminal side of the GI tract is exposed to dietary components and gut microbiota, moreover, gut tissue is housed by 70% of immune cells and innervated by neurons which connects the gut and brain, involving constant communication between the gut and the brain [2]. Communication between the gut microbiota and brain involves the four main routes; the first important mode includes the activation of vagus nerve which connects the muscular and mucosal layer of GI tract to the brain stem. Recent reports show that enteric pathogen and probiotics regulates the host behaviors like anxiety, feeding, and depression by altering $\gamma$-Aminobutyric acid (GABA), oxytocin and brain derived neurotrophic factor (BDNF) signaling in brain via activation of vagal neurons [90,91]. Though, one report showed that indole, a neurotrophic factor signaling in brain via activation of anxiety-like behavior in rats via vagus nerve activation, but specific metabolites mediating these effects still need to be identified [92]. The second route of communication influencing brain activity directly or indirectly involves the signaling through serotonin released by enterochromaffin cells (EC) present in gut lining. A study showed the increase in serotonin and serotonin precursor levels in mouse models of depression, when treated with probiotic *Bifidobacterium* spp., improving their depressive state [93]. Similarly, it was reported that metabolites from spore-forming bacteria (*Clostridium* spp.) were able to stimulate serotonin production from EC [94]. Thirdly, gut microbiota plays an essential role in development, maturation and activation of microglia. In a study, it was reported that germ free (GF) mice carries larger number of immature microglia than conventional mice, moreover when treated with *Bifidobacterium* spp. activates microglial cells through transcriptional activation [95]. Changes in microglia functioning have been observed in behavioral and NDDs, showing the influence of gut microbiota on NDDs mediated via microglia. Gut microbiota also affects the nervous system via systemic immune system i.e., cytokines and chemokines. Study showed that GF mice possess greater blood–brain barrier (BBB) permeability in comparison to conventional mice, thus making brain accessible to microbial products subsequently leads to neuropathological conditions [96]. Last but not the least, gut microbiota communicates through a direct transfer of chemical signals to the brain. For example, fermentation of dietary fiber by intestinal bacteria produces short chain fatty acids (SCFAs) which have been shown to regulate neuroplasticity in CNS, and was also reported to improve the depressive behavior in mice [97]. Furthermore, gut microbiota like *Bacteroides*, *Bifidobacterium*, *Parabacteroides* and *Escherichia* spp. are capable of producing neurotransmitter GABA which implicates that gut microbiota modulates the concentration of neurotransmitters in host organism [98].

**Gut microbiota-mediated oxidative stress and neurodegeneration**

Four main phyla of commensal bacteria colonize in human gut which includes Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. Among them, Firmicutes including *Lactobacillus*, *Streptococcus*, *Mycoplasma* and *Clostridium* along with Bacteroidetes encompass 90% of the total. Both commensal and pathogenic bacteria in gut are able to alter the cellular ROS by modulating mitochondrial activity [99]. Commensal bacteria produce formylated peptides which bind to G protein-coupled receptors (GPCRs) on macrophages and neutrophils, which triggers inflammation in epithelial cells. This process results in superoxide production by NOX-1, increasing cellular ROS [100]. Gut *Lactobacilli* and *Bifidobacterium* possess the ability to convert nitrate and nitrates into NO, making the gut epithelia a rich source of NO. Similarly, *Streptococcus* and *bacilli* produce NO from L-arginine using NOS [101]. NO in nanomolar concentration is considered to be neuroprotective and is a neurotransmitter for noradrenergic, noncholinergic enteric neurons. While at a higher concentration, it results in the detrimental effect caused by the production of reactive oxygen and nitrogen species (RONS) like superoxide and $\text{H}_2\text{O}_2$, which further forms highly reactive hydroxyl radicals associating it to neuroinflammation, axonal degeneration and NDDs [18]. Beneficial metabolites like SCFAs produced by gut bacteria help to reduce ROS by influencing mitochondrial activity. This will be discussed more in detail in another section.

Membrane associated molecular pattern (MAMP) maintains structural integrity and basic functions of all classes of microorganisms and are detected even by brain. These are diverse chemical groups including peptides, nucleotides, carbohydrates and lipids [102]. When such molecular patterns are undetected by the host, it may escort acute to chronic inflammation and is found to alter brain development and function. These highly conserved structural motifs bind to pattern recognition receptors (PRRs) present on cells of innate immune system, thus inducing mitochondrial ROS production and activation of NF-κB pathway leading to inflammatory responses, causing neuronal stress and cell death [103]. In a recent study, it was reported that bacterial cell-wall component peptidoglycan translocate to the developing brain affecting gene expression and causes a change in social behavior [104]. Similarly, lipopolysaccharide present in Gram-negative bacterial cell-wall was found to impair fetal brain development, acute depression and cognitive impairment in mice [105]. Moreover, acute and chronic exposure of MAMP was observed to be a responsible factor.
in developing disease symptoms in PD, autism spectrum disorder (ASD) and synucleinopathy models [106]. Apart from MAMPs, bacterial toxins produced by opportunistic pathogens also exert a negative impact on host nervous system. Lethal toxins like toxin B, enterotoxin and epsilon toxin produced by Clostridium spp. were discovered to decrease neuronal viability and also inhibit the release of neurotransmitters by reaching the brain via disrupted BBB [107]. Enterotoxins and cereulide produced by Staphylococcus spp. and Bacillus spp. were found to induce vomiting and sickness behavior by stimulating vagus nerve [108, 109]. Pathogenic bacteria like Salmonella and E. coli are able to degrade sulphur containing amino acids, thus producing hydrogen sulphide (H2S) in the gut. An increase in H2S levels imposes change in various metabolic activities like increased lactate and decreased ATP production, inhibition of cyclooxygenase 2 (COX-2) activity [110], decreased consumption of O2 by mitochondria and an increased expression of pro-inflammatory cytokines [111] and is known to stimulate hypertension and neuroinflammation [112]. Fig. 1 shows the role of gut microbiota-mediated oxidative stress in neurodegeneration.

Etiopathology of NDDs like AD and PD involves the intraneuronal protein misfolding and its aggregation. Moreover, oxidative stress is also considered as one of its pathogenic factors, but the exact underlining mechanism is still unknown. The first evidence showing the relationship of NDD pathology with gut microbiota was shown by Heiko Braak group, where they found the α-synuclein aggregation in submucosal Meissner's and Myenteric Auerbach's plexuses in the gut of PD patients, suggesting the role of gut microbiota in initiating the α-synuclein aggregation in the gut, which is then ascended trans-synaptically to CNS neurons causing neurodegeneration [113]. Interestingly, microbiota-mediated proteinopathy and neuroinflammation is termed as “mapronosis” showing their interim relationship [114]. So far, numerous studies have shown the altered gut microbiota composition in neurological disease state in comparison to healthy individuals, but further work is needed to identify the mechanisms on how bacteria and bacterial factors influence the disease progression. Here, we describe the recent work depicting the link between gut bacteria, oxidative stress and NDDs, focusing on AD, PD and TBI.

**Gut microbiota-mediated oxidative stress in Alzheimer’s disease**

Alzheimer’s disease (AD) is the leading cause of dementia, affecting over 50 million population worldwide, where its prevalence is higher in older population, with about 80 per 1000 individuals above 85 years of age. Non-symptomatic pathology of AD is thought to begin approx. 20 years before the symptoms like memory loss and cognitive deficits arise [115]. Pathological changes in brain associated with AD include the extracellular accumulation of protein amyloid-beta (Aβ-amyloid plaques) and the intracellular accumulation of tau proteins (tau tangles) [116]. This abnormal accumulation of proteins leads to activation of microglia for the clearance of Aβ and tau proteins, but with subsequent aging, chronic inflammation occurs causing neuronal cell death, leading
to atrophy [117]. Despite of rare genetic mutation causing Aβ accumulation 20 years before onset, followed by decreased glucose consumption by brain 18 years before and atrophy began 13 years before the development of disease [118], many cross-sectional studies have documented modifiable risk factors as an etiopathology of AD [119]. Among the possible risk factors, the role of oxidative stress and gut microbiota has attracted the scientific community and is considered as an immediate plausible consequence of neurodegenerative processes.

In addition to high energy demands of brain, the link between oxidative stress and AD is reflected in many studies which showed the alteration in antioxidant defense system of the brain i.e. changes in activity and levels of SOD and catalase enzyme [120]. Likewise, oxidative stress biomarkers like malondialdehyde, 4-hydroxynonenal, and F2-isoprostane (lipid oxidative damage); protein carbonyls and 3-nitrotyrosine (products of protein oxidation), 8-hydroxydeoxyguanosine (nucleic acid oxidation) were found at high levels in blood and CSF [120], also their concentration was found proportional to that of cognitive impairment and brain weight [121]. ROS production in AD brain is also characterized by dysfunction in cellular organelles like mitochondria (deficiency of cytochrome C oxidase) [122], endoplasmic reticulum due to UPR [123], accumulation of metal ions in neurotic plaques [124] and due to the hyperactivation of microglia followed by the overexpression of NADPH oxidase [125]. There is also an inter-relationship between Aβ deposition and oxidative stress i.e. Aβ aggregation induces oxidative stress (also in organelles like mitochondria, ER and golgi apparatus) and oxidative stress induces Aβ accumulation [126]. Even, aggregation of tau proteins in neurons leads to decreased NADH-ubiquinone reductase activity resulting in increased ROS production and mitochondrial dysfunction [127].

Recent facts and figures show that AD is not only a result of confined brain inflammation but is also a consequence of peripheral inflammation [128]. This is supported by the fact that gut dysbiosis leads to inflammation which increases with age, disruption of BBB, activation of immune system followed by neurodegeneration, on the other hand, healthy and well-balanced gut helps to decrease detrimental effects produced by ROS [19]. Individuals suffering from AD have been identified with decreased population of commensal bacteria such as Bifidobacterium spp. and Firmicutes, and an increased abundance of Escherichia, Shigella spp. and Bacteriodetes, followed by increased inflammation and Aβ accumulation [129]. Similarly, decline in Aβ plaque formation was seen in APP/PS1 mice model when treated with the combination of broad-spectrum antibiotics [130]. Likewise, 5xFAD mouse model of AD showed shifts in microbiota population towards proinflammatory species along with the changes in amino acid catabolism, and conversely, treatment with antibiotics reversed the effects, suggesting the possible link between severity of disease and transformed gut population [131]. Microbial amyloid protein formed in the gut activates the Toll-like receptors (TLR) and cluster of differentiation 14 (CD14) facilitated immune response leading to overlooked misfolded Aβ with impaired Aβ clearance, subsequent increasing cytokine production resulting in disrupted intestinal and BBB [114]. Also, it was shown that levels of enteric hormones decrease in AD patients, on the contrary, gut microbiota metabolites like H2S and trimethylamine increase, enhancing its rigor [132].

Age-related decrease of gut microbial biodiversity is also considered as one cause of dementia. It has been shown that with growing age, there is a decrease in Bifidobacterium spp. and an increase in Proteobacteria, where dementia results not because of decrease in SCFA’s but due to interference in lipid metabolism. Bifidobacterium plays an important role in regulating cholesterol levels directly facilitating its fecal elimination and indirectly by increasing the serum leptin levels, thus involved in maintaining hippocampal plasticity and memory functions [133,134]. Gut bacteria like Lactobacilli and Bifidobacterium metabolize an inhibitory neurotransmitter GABA [135]. In a study, it was observed that synaptic plasticity in hippocampus was altered in APPSwe/PSN1 DeltaE9 bigenic mouse model of AD, where reduced GABA production was found with a concomitant increase in glutamatergic neurotransmission [136,137]. Although, reports show that phylum cyanobacteria produces neurotoxins causing cognitive impairment, but no relation has been observed with AD [138].

Another possible connecting link, cerebral amyloid accumulation and gut microbiota involve the mechanism of cross seeding of microbial amyloids in a manner similar to prion propagation, thus different amyloid conformers formed induces toxicity at distinct levels in their cellular targets, hypothesizing the existence of AD phenotypes [139]. In addition to gut microbiota, a link between commensal bacteria in oral cavity and AD was also studied. Interestingly, poor oral hygiene and teeth loss was found to cause an increased risk of early onset of AD [140].

Gut microbiota-mediated oxidative stress in Parkinson’s disease

Parkinson’s disease (PD) is pathologically characterized by progressive degeneration of dopaminergic neurons, aggregation of phosphorylated protein α-synuclein, excessive ROS production, mitochondrial dysfunction and microglia activation [141]. Symptomatically, it is characterized by inability of the patients to control voluntary movements (tremors, muscle rigidity, difficulty walking and hunched posture) due to damage in substantia nigra and striatum regions of the brain. It is the second most common NDD affecting more than 1% of elderly population worldwide [142]. The first report on relationship between gut and PD was mentioned in an essay on shaking palsy by James Parkinson in 1817 [143]. Braak’s hypothesis supported this view showing the initiation of pathology in the gut, then affecting the brain. Accumulating evidences show that gut inflammation, early accumulation of phosphorylated α-synuclein transcending to the dorsal motor neuron of the vagus nerve, constipation problems and increased intestinal permeability are common in PD patients, suggesting a strong relationship between gut microbiota and PD pathogenesis [144]. Moreover, it was observed that risk of developing PD decreases in those individuals who have gone for vagotomy [145]. In addition, lower levels of GSH, and higher level of iron and H2O2 makes substantia nigra pars compacta (SNc) neurons susceptible to oxidative stress [146]. Also, lipid peroxidation and dopamine oxidation in this region leads to neuronal cell death. Studies also show that mitochondrial respiratory chain dysfunction leads to excessive ROS production. It is supported by the fact that inhibitors of complex 1 induces cytotoxic effects on dopamine neurons [147], also patients with pathology of α-synuclein, phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and Parkin were detected to have mitochondrial dysfunction with increased oxidative stress [148]. Similar to AD, aggregation of abnormal protein α-synuclein is interrelated to increased oxidative stress and vice versa. Coming to the role of gut microbiota, some pathogenic spp. release toxins causing mitochondrial dysfunction in cells of the gut and ENS resulting in neurodegeneration [149]. The pathogenic bacteria increase in gut of PD patients and their microbial products are directly involved in PD pathogenesis. In support of this fact, recently it was reported that pathogenic bacteria Escherichia coli produces amyloid protein known as curli, which promotes α-synuclein aggregation in gut and brain and was observed to cause motor deficits in mice [150]. On the other hand, when mice were treated with gut restricted amyloid inhibitor, it has shown the improvements in motor functions along with amelioration of...
constipation [151], showing the involvement of gut in etiology of PD symptoms, supporting Braak’s hypothesis.

Gut inflammation caused by gut bacteria can be directly correlated with progressive neurodegeneration in PD. Though serum metabolic profile and gut composition are found altered in PD patients, it was observed that in severe PD condition, Enterobacteriaceae level enhances in gut with very low level of anti-inflammatory bacteria, also showing its parallel association with gut inflammation in Crohn’s disease [152]. This shows that patients with Crohn’s disease possess very high risk of developing PD. Similarly, it was observed that Citrobacter rodentium infection in mouse model (PTEN induced Kinase 1 (PINK1) knockout mice), aggravated PD symptoms by inducing gut inflammation [153]. In addition to induce inflammation, gut microbiota also exerts metabolic effects, like its metabolites β-glucoronate, tryptophan and SCFAs were found to be altered in case of PD patients [154]. Recently, one striking attribute of gut microbiota was also reported showing that it acquires the ability to reduce the efficacy of anti-PD drugs either by decreasing its bioavailability or by increasing drug inactivation, as observed in the case of standard levodopa treatment [155,156]. Inclusive of these studies, decreased production of H2 by gut bacteria is also found to be one of the contributing factors in PD [157]. A recent report showed that when 50% H2 saturated water was given to rat and MPTP mouse model of PD, it was found to be successful in reducing neuronal loss in substantia nigra and also the oxidative stress markers and when double blind randomized trial was performed in humans, an improvement in motor ratings of PD patients was observed [157,158]. Further, towards this notion, recent work on GF mouse model of PD with overexpressed human α-synuclein gene showed the reduced level of SCFAs along with the decreased microglia activation and improved motor functions which suggests the direct involvement of gut microbiota in enhancing PD. In addition to it, when gut microbiota from PD patients was transplanted into GF α-synuclein overexpressed mouse model, worsened the motor symptoms, suggesting the role of dysfunctional gut microbiota in PD patients [151], similarly, mouse model treated with neurotoxin showed altered gut microbiota composition with increased levels of pathogenic Enterobacteriaceae [159]. Furthermore, increased Firmicutes to Bacteroides ratio (condition also in gut inflammation) was observed in mice treated with pesticide rotenone [160]. Strikingly, some specific bacterial species like Proteus mirabilis were found to bolster neurodegeneration in mice [160]. Taken together, these studies suggest that gut microbiota exacerbates neuronal dysfunction and neuroinflammation in both human and animal models of PD.

Gut microbiome and traumatic brain injury (TBI)

Traumatic Brain Injury (TBI) is one of the most prevalent injury types sustained in the world population with an annual incidence of ~1.4 million cases in the United States, and is among the major cause of death and disability [161]. The disabilities which occur in TBI not only includes a primary mechanical damage of brain but involves post injury secondary damages, which takes place at the cellular and molecular level, and may lead to metabolic anomalies like mitochondrial dysfunction, oxidative stress, inflammation, microglia activation, excitotoxicity, resulting in temporary or lifelong cognitive impairments [162]. Moreover, severity of TBI is not only focused on brain but can be a multiorgan damage and is considered as a heterogenous pathobiological condition. Due to the heterogenous nature of brain injury, therapies for TBI-induced neuropathologies are still lacking, pertaining to the consideration of novel therapeutic regimens. Towards this approach gut eubiotic therapeutics have gained much attention, because of its capability to restore the bifacial relationship between gut dysbiosis and TBI [163,164].

Growing line of evidences reveal that there exists a bidirectional relationship between a gut microbiome and TBI injury. One of the systemic manifestations of TBI has been observed as a disruption of intestinal motility and permeability, mucosal damage, histopathological alterations of intestinal villi, thus indicating the perturbation in the composition of gut microbiome [165-167]. Conversely, it has been observed that gut dysbiosis also influences the pathophysiology of traumatic CNS injury, alterations in BBB permeability and activation of microglia, leading to severe repercussions [168-170]. Recent report showed that a mice exposed to mild and repetitive brain injury for 20 days show a progressive emergence of white matter damage, cognitive deterioration and a mild, transient gut dysbiosis [171]. Similarly, it was observed that depletion of gut microbiota in murine model of TBI prior to and following brain injury resulted in an increased CA1 hippocampal neuronal density, attenuated associative learning deficit and had reduced lesion volume [172]. Recent study also claims that gut dysbiosis takes place after traumatic spinal cord injury which resulted in intraspinal inflammation and lesion pathology [173]. Also, changes in two major order of bacteria in gut Bacteroidiales and Clostridiales was observed i.e ~30% decrease in phylum Bacteroidetes and ~25% increase in phylum Firmicutes. This was accompanied by the consistent changes in minor taxa including Anaeroplasmatales, Turicibacterales and Lactobacillales. Such changes were found to be persistent and lasted for about 4 weeks post injury [174]. A similar modulation in gut microbiome population, but an inverse relation of decrease in Firmicutes and an increase in Bacteroidetes was found to occur 2 h following injury and being persistent for about 7 days in rodent model of moderate TBI [175]. Likewise, recent report showed that their occurs a rapid significant decrease in three species Lactobacillus gasseri, Ruminococcus flavaefaciens, and Eubacterium ventriosum and an significant increase in Eubacterium sulci, and Marvinhynantia formatexigens in human gut microbiome just in 24 h after TBI in mice [176]. Furthermore, a decrease in Bacteroidales, Fusobacterales, and Verrucomicrobiales, along with an increase in Clostridiales and Enterococcus within 72 h were observed in severely injured patients with polytrauma [177]. Gut microbiota also plays a very important role in recovery from TBI, as observed in a recent report where gut dysbiosis induced by a broad spectrum antibiotic before, during and after TBI resulted in an increased neuronal loss, suppressed neurogenesis as well as altered the microglia and peripheral immune response along with the modulation in fear memory response [178]. Thus, the influence of gut microbiota on TBI patients is of paramount clinical significance because TBI patients become susceptible to alterations in gut microbiota due to regular antibiotic administration and prolonged hospitalization. Furthermore, detection of gut microbiota modulation might provide a diagnostic tool for the identification of TBI severity, thus providing targeted therapeutic approaches.

CNS antioxidants and neuroprotection

CNS is highly vulnerable to oxidative stress and leads the neurological disorders. High level of ROS is generated during the functioning of CNS due to high O2 demand and rush of peroxidation-susceptible lipid cells. This oxidative metabolism generates reactive species for transmitting redox signals to regulate critical functions such as synaptic plasticity [29,179]. Antioxidants whether enzymatic or non-enzymatic, endogenous, or exogenous, protects the brain against the oxidative stress by preventing the generation of ROS or by scavenging the free radicals or inactivate the free radical product. The first line of antioxidative
defence mechanism involves the use of endogenous enzymes like SOD, glutathione peroxidase (GPx), glutathione reductase, and catalase [180]. Whereas, second line of antioxidative defence involves the use of endogenous non-enzymatic molecules like thioredoxin, ferritin, transferrin, ceruloplasmin, albumin, and metallothionein. Also, enzyme co-factors, i.e., coenzyme Q and alpha-lipoic acid, and metabolites, i.e., bilirubin, melatonin, and uric acid plays an important role in antioxidative defence mechanism [181,182]. Similarly, natural dietary compounds like vitamins A, E, and C, flavonoids, phenolic acids, and carotenoids are also known to possess a strong possible antioxidative defence against oxidative stress-induced neurodegeneration [182].

The antioxidant enzymes such as SOD decreases the concentration of superoxide anion by catalyzing the dismutation of superoxide to O2 and H2O2; GPx reduce H2O2 and lipid peroxides; thiol-specific peroxidases such as peroxiredoxins reduce the amount of hydroperoxides, and catalase transforms H2O2 to H2O and ordinary molecular O2 [29,183]. The free radicals activate the transcription of genes involved in antioxidative pathways and protect the cells from adverse effects. Glutathione is present in low amount in the CNS which reacts with free radicals in its reduced form to convert the H2O2 to H2O by self-catalyzing to G5–G5 and regenerates again to glutathione by a reductase [183]. Insufficiency of glutathione may limit the activity of peroxidases that could make the neurons more susceptible to oxidative stress. In-vivo and in-vitro studies performed till date showed that the SOD and catalase improves the neuronal survival following the Aβ-induced neuronal toxicity [184-187]. Likewise, both thioredoxin and thioredoxin reductase are widely expressed in brain and are known to exert neuroprotective effect against oxidative stress models of HD and AD [188,189].

Another very important pathway is Kelch-like ECH-Associating protein 1 nuclear factor erythroid 2 related factor 2-antioxidant response element (Keap1-Nrf2-ARE). Keap1-Nrf2-ARE is highly expressed in neurons and linked with the defense mechanisms against oxidative stress associated with NDDs. It modulates the activity of SOD, thioredoxin, peroxiredoxins, and GPx via transcriptional regulation [190]. The importance of NF-xB is also reported as a redox-sensor in CNS that is activated by ROS. Moderate level of ROS phosphorylates NF-xB inhibitor that results in NF-xB activation. Activated NF-xB regulates the expression of anti-apoptotic and inhibits caspase-dependent cell death pathways. However, high levels of ROS inhibit the binding of NF-xB via inactivating it. This mechanism promotes the apoptosis of cells and halts the pro-survival pathways [29]. The regulation of antioxidant metabolism of the CNS is tightly controlled where the role of gut microbes is highly dynamic.

Gut microbiota in neuroprotection

Gut microbe-microbe and microbe-host interactions regulate the level of exogenous and endogenous ROS via various metabolites production such as absorbable vitamins, polyphenols, SCFAs, BDNF, diffusible antioxidant and oxidant gases, etc. Gut microbes also control the permeability of metabolites to BBB, tight junction integrity and intestinal barrier, modulate the immune system and impede the intestinal colonization of pathogens [191]. The vagus nerve of the parasympathetic nervous system senses the gut metabolites and communicates to CNS about the gut information to generate specific responses. Under the stress condition, the vagal tone is repressed and shows detrimental effects such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) due to dysbiosis [192]. Aβ proteins involved in the pathogenesis of AD are expressed by gut bacteria such as Escherichia coli and Salmonella enterica in ENS [183]. Beneficial gut microbes also produce dopamine, serotonin, and GABA. These are the CNS neurotransmitters which modulate the ENS activity and may correlate [179]. In some studies, it was revealed that gut microbes manage the activation and maturation of microglia, and activated microglia releases significant amounts of inducible nitric oxide synthase (iNOS) to regulate NO production. Dysbiosis provokes the inflammatory iNOS and causes neuroinflammation [183].

As we have seen the potential role of gut microbiota as well as essential role of oxidative stress in mediating neuronal disorders, in recent years, a growing need and a major scientific focus is on developing antioxidant-based therapies for treating oxidative stress-induced NDDs. Antioxidants are chemical or natural substances capable of counteracting oxidative stress induced by ROS/RNS [193]. Though a potent therapeutic effect of antioxidants has been observed on diseases like diabetes, arthritis, cataract and osteoporosis, antioxidant therapies used for CNS disorders are limited and still requires deep mechanistic understanding [194]. Contrary to the antioxidant therapies, dichotomous role of gut microbiome is observed, which one hand is responsible for the basic underlying mechanism of neurodegeneration (gut dysbiosis and neuroinflammation) and on the other hand, gut microbiome and its metabolites regulate many associated pathways suggesting their neuroprotective therapeutic role. Microbial molecules like protein, vitamins are produced via multistep biosynthetic pathway, which may exert beneficial or detrimental effects on the host system [16]. Therefore, a healthy gut microbiome maintained with a proper diet including prebiotics and probiotics is a prerequisite for maintaining neuronal health [195]. Fig. 2 shows the role of gut microbiota metabolites along with the modulation procedures on gut microbiota and their effect on NDDs. Here, we review how bacterial metabolites (their natural, transformed, and dietary metabolites) help to combat oxidative stress-induced neuronal damage. Moreover, we will further discuss about the role of antioxidative and anti-inflammatory probiotics/prebiotics in neuroprotection. Table 1 shows the recent studies on gut microbiota showcasing its neuroprotective role.

Gut microbiota metabolites in neuroprotection with their cell-specific responses

Gut microbiota interaction with host molecules

Bile acids. Bile acids are produced in liver and are released in the intestinal lumen, primarily involved in the solubilization of lipids and fat-soluble vitamins, signaling in energy metabolism and is also known to play an important role in physiology and pathophysiology of the brain [196]. Bile acid influences neuronal activity in different brain regions and also vagal neuronal activity either by directly binding the receptors in brain crossing BBB, or by indirectly inducing the release of fibroblast growth factor (FGF) and glucagon-like peptide 1 by binding to gut receptors [197]. Bile acids like ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) possess neuroprotective properties and lack of cytotoxicity as proved in their phase III clinical trials [198] and in an animal study [199], respectively. Recent data shows that TUDCA helps to attenuate autophagy, α- synuclein aggregation and protein oxidation in chronic mouse model of PD [200]. Moreover, it helps to prevent neuronal apoptosis in rats affected by subarachnoid hemorrhage via Takeda G protein-coupled receptor 5/sirtuin-3 (TGR5/SIRT-3) pathway [201]. Likewise, UDCA showed a neuroprotective effect in charged multivesicular body protein 2B (CHMP2B) Intron 5 models of frontotemporal dementia [202]. Gut microbiota in the intestinal lumen converts primary bile acids (cholic acid and chenodeoxycholic acid) into secondary bile acids by the action of dehydratases, involves deconjugation of amino acids with bile salt hydrolases and other enzymatic processes, which alters their nuclear receptor binding, solubility and
Circulation [203]. Changes in secondary bile acid levels have been found in human and mouse model of AD [204], PD [205], ASD [206] and multiple sclerosis [207]. Also, bacteria-modified bile acids were found to be neuroprotective in case of ALS and stroke [208]. Modulation of gut microbiota community can cause changes in the level and properties of bile acids, which might be neurondegenerative or neuroprotective. It has also been reported that gut microbiota-mediated increase in deoxycholic acids induces the release of neurotransmitter serotonin in EC in mice [94]. Bile acid metabolites were found to improve demyelination [209] and reducing oxidative stress [210], potentiating its neuroprotective role via acting on oligodendrocytes and microglia, respectively. Still, the potential role and effects of microbiota manipulated bile acid is unknown and remains to be defined clearly.

Steroid hormones. Signaling by steroid hormones is crucial for brain development and functions (memory, decision making and sexual behavior) [211]. While circulating throughout the body, steroid hormone encounters microbiota in intestinal lumen [212]. Gut bacteria modify steroid hormone in a deconjugation reaction mediated by the action of β-glucuronidases and β-glucosidases, which reactivates the hormone and prevent it from excretion. Thus, gut microbiome influences the level of active and inactive steroid hormones via degradation and activation pathways [213]. Androgens and oestrogens are found to be influenced by gut microbiome. A large number of enteric bacteria were found to metabolize oestrogens [214] and oestrogens also undergo oxidation–reduction reactions in faecal samples [215], suggesting the role of gut microbiota. It has been observed that gut microbiota also possesses the ability to convert testosterone [216] and cholesterol to androgens [217]. Microbial influenced oestrogens were found to be neuroprotective, showing anti-inflammatory effects on microglia [218]. Also, altered gut microbial community was observed to result in low levels of oestrogen, which resulted in chronic inflammation [219] and cognitive impairment [220]. Oestrogenic molecules also affects differentiation and myelination in oligodendrocytes [221]. Recent report also showed that even progesterone treatment in MPTP parkinsonian mouse model showed neuroprotective, anti-inflammatory and immune-modulatory effects, but whether the neuroprotective role begins in gut or brain is still unknown [222].

Gut microbiota interaction with dietary molecules
Amino acids. Dietary amino acids can also be metabolized by gut microorganisms and their effect on the brain varies depending upon the type and frequency of diet intake [223]. Although, gut microbiota encoded amino acids circulate in the host, but those affecting CNS are dietary amino acids metabolized by gut bacteria [224]. Aromatic amino acids like tyrosine, tryptophan and phenylalanine are metabolized by gut bacteria into SCFAs, indole derivatives, neurotransmitters, organic acids, amines and ammonia [225]. The end product of tyrosine metabolism is the formation of two catecholamines, dopamine and noradrenaline from tyramine intermediate. In vitro studies showed that large number of gut bacteria can produce noradrenaline in millimolar range [226]. Recent report showed that non-adrenaline increases the supply of glutathione from astrocytes by stimulating β-3 adrenoceptor, thus protecting neurons from H₂O₂-induced neuronal death [227]. It is found that tyrosine is also metabolized by gut.
Amino acid glutamate is also converted by gut bacterial glutamate decarboxylases to form GABA, an inhibitory neurotransmitter, which is observed to reduce depression and anxiety symptoms in mouse model [90]. In case of amino acid arginine, it is metabolized into four polyamines agmatine, putrescine, spermidine and spermine, which act via glutamate receptors and are involved in maintaining synaptic plasticity and memory formation [233]. Agmatine shows the therapeutic effects in case of CNS disorders while acting as a ligand for β2 adrenergic and imidazole receptors in brain [234]. Spermidine also showed its neuroprotective effect in 3-nitropropionic acid 3-NP model of HD [235]. Moreover, agmatine shows the potential role of gut microbial endocrinology in neuroscience.

Dietary fibers. Undigested dietary fibers like complex carbohydrate polysaccharides are acted upon by intestinal microbial enzymes glycosidase hydrolases and polysaccharide lyases and are converted

| Microbiota | Neurodegenerative disease | Model | Study outcome | Reference(s) |
|------------|---------------------------|-------|---------------|--------------|
| Lactobacillus buchneri KU200793 | PD/AD | SH-SYSY cells | Treatment with heat killed strain reduced Bax/Bcl-2 ratio and increased BDNF expression | [288] |
| Lactobacillus delbrueckii ssp. bulgaricus B3 and Lactobacillus plantarum | AD | SH-SYSY cells | Protected cells from Aβ-induced cytotoxicity | [22] |
| Lactococcus lactis pFG(SQSTM1)-engineered | AD | 3Xtg-AD mice | Diminished oxidative stress and inflammation, reduced levels of amyloid peptides and improved memory | [289] |
| Lactasebacillus rhamnous HA-114 | ALS/HD | Caenorhabditis elegans and mouse model of ALS | Restores lipid homeostasis and energy balance through mitochondrial β oxidation | [290] |
| Clostridium butyricum | AD | APPswe and PS11E9 mutant transgenic mice | Prevents Aβ deposition, microglia activation, production of TNF-α and IL-1β | [291] |
| Lactobacillus fermentum NCIMB 5221 | AD | | Ferulic acid produced by bacteria reduces oxidative stress, Aβ fibrillation and improves memory | [292] |
| Lactobacillus plantarum WCFS1, E.coli Nissle and Bifidobacterium infantis spp. | AD/AD | | Proficient in producing butyrate, propionate and acetate | [293] |
| Lactobacillus plantarum MTC1325 | AD | D-galactose-induced AD mouse model | ATPase enzyme levels and Na+ and K+ ATPase activity was restored required for potential neural activity | [294,295] |
| SLAB51 (Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus, L. brevis) | | | | [274] |
| Ruminococcus albus | NA | Oxidative stress induced Sprague Dawley rats | Reduced ROS levels and increased SOD and GSH levels in oxidative stress condition | [23] |
| Lactobacillus acidophilus and Bifidobacterium infantis | PD | Human PD patients | Reduced symptoms of abdominal pain and bloating | [296] |
| Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum | PD | Human PD patients | Decreased movement disorder society-unified Parkinson’s disease rating scale scores | [297] |
| Lactobacillus casei Shirot | PD | Human PD patients | Improved abdominal symptoms | [298] |
| Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum | AD | Human AD patients | Decreased C- reactive protein (CRP) levels and insulin resistance and neuronal cell death | [299] |
| Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum | PD | 6-OHDA treated male Wistar rats | Improved rotational behavior, cognitive function, lipid peroxidation, and neuronal damage | [300] |
| Lactobacillus acidophilus, Bifidobacterium bifidum and Bifidobacterium longum | AD | Animal model of AD | Improved cognitive performance and restored synaptic plasticity | [301] |
| L. casei LC122 and B. longum BL986 | Age related neurodegeneration | C57BL/6 mice | Attenuated oxidative stress, improved gut barrier function and inhibited hepatic lipid accumulation | [302] |
| Lactobacillus johnsonii | AD | Germ free mice | Decreased kynurenine and increased serotonin levels | [303] |
to SCFAs via anaerobic fermentation [238]. Butyrate, acetate, and propionate comprise SCFAs, which act as a source of energy for colonic epithelial cells. Besides this, it also enters systemic circulation, subsequently affecting physiological functions of many organs including neural development and functions directly or indirectly [238]. Reports reveal that when gut microbiota of AD mouse model was modulated by treating with a mixture of probiotics or by using anti-inflammatory SCFAs, it helps to counteract the progression of the disease [239]. Similarly, SCFAs were found effective to exacerbate motor symptoms in GF mouse model of PD [240]. SCFA, acetate crosses the BBB and activates the neurons and modulates the level of neurotransmitters and neurotrophic factors [241]. In a study, it was shown that propionate and butyrate influence the intracellular potassium level in neurons [242]; Butyrate acts as a potent inhibitor of enzyme which regulates epigenetic gene activation (histone deacetylase) and is found to act as a potent anti-inflammatory agent in mouse model of AD, PD, HD, genetic gene activation (histone deacetylase) and is found to act as a potent anti-inflammatory agent in mouse model of AD, PD, HD, stroke and memory impairment [238]. Interestingly, SCFAs interfere in the interaction between Aβ peptides to form neurotoxic oligomers, thus preventing AD pathology [243]. It was also reported that fecal microbiota transplantation from wild type mice to the animal model of PD along with the butyrate administration remarkably improved the motor symptoms and dopamine deficiency [244]. When we look at the cell-specific responses, butyrate has been shown to reduce neuroinflammation and oxidation in astrocytes in vitro, and acetate is used as a source of energy by these cells [245]. In a study, it was observed that SCFAs increases the expression of tight junction proteins by binding to the SCFA receptors on endothelial cells, thus helps in decreasing the permeability of BBB and preventing the LPS-induced seizures and stroke [246]. SCFAs reduce oxidative stress in the brain by decreasing microglial activation [247], thus combating neuroinflammation in AD and PD. Taken together, SCFAs obtained from dietary fibers helps to improve brain health, depending upon the gut health of the individual.

**Polyphenols.** Polyphenols are bioactive molecules present in plants that plays a fundamental role in growth, protection and reproduction in plants [248]. Polyphenols are classified as flavonoids, phenolic acids and tannins. The molecular structure of polyphenols i.e., positions of hydroxyl group and nature of the substitution of aromatic rings affords them the ability to scavenge free radicals [248] and are widely studied as an antioxidative therapy for the treatment of NDDs [249]. Unabsorbed polyphenol is converted into bioavailable and bioactive metabolites [250] in the host by the action of gut microbiota via hydrolysis and esterification, which is further followed by modifications like methylation, sulfation, hydroxylation before they reach the peripheral tissues [251]. Studies on different polyphenols like resveratrol obtained from grapes and wines, curcumin and epigallocatechin-3-gallate from green tea exerts neuroprotective effects by activating protein kinase pathways like Keap1/Nrf-2/ARE, which are major pathways in alleviating both endogenous and exogenous ROS. It has also been reported that bacterial polyphenolic metabolites such as 3-hydroxybenzoic acid and 3-(3′-hydroxyphenyl)propanic acid inhibits amyloid aggregation, thus facilitates to inhibit the progression of AD [252]. Similarly, it has been observed that a flavonoid quercetin act as BACE-1 inhibitor [253]. Moreover, natural flavonoid proanthocyanidins mitigate rotenone-induced oxidative stress in dopaminergic neurons in vitro [254]. Also, polyphenols like ferulic acid produced by gut microbiota promote neurogenesis and have shown the neuroprotective role in mouse models of AD [255] and cerebral ischemia [256]. Equol and Enterolactone are also derivatives produced by gut bacteria by metabolizing phytoestrogen, one of the polyphenols [257], which might have an effect on classical neuroprotective pathway mediated by oestrogen receptors. Interestingly, polyphenols can also modulate the composition of gut microbiota [258], which further convert them into anti-inflammatory and neuroprotective metabolites.

**Vitamin B and vitamin K**

Gut microbiota also acts as an important source of vitamins particularly vitamin B and K, which are not only essential for the gut microbial metabolism but also show it effects on physiological pathways in the host [259]. Gut bacteria like Escherichia coli, Klebsiella pneumoniae, Propionibacterium, and Eubacterium produces vitamin K, B2 (riboflavin) is produced by Bacillus subtilis and E. coli; B9 (folic acid) by Bifidobacterium, Lactococcus lactis and Streptococcus thermophilus; and B12 (cobalamin) is produced by Lactobacillus reuteri and Propionibacterium freudenreichei [260]. Though dietary vitamins are absorbed through small intestine, uptake of microbiota-derived vitamins occurs in the colon. To prevent hemorrhagic disease in neonates, prior to the establishment of gut microbiota, vitamin K is administered as an essential agent for the process of thrombosis [261]. Moreover, vitamin B and K are found to be important for brain development and function [262]. In the case of NDDs, many studies have shown the effective role of vitamin B and K in improving neuronal health. Vitamin K deficiency was found to be correlated with the pathogenesis of AD, similarly, increased uptake of dietary vitamin K has helped to improve the memory functions in elderly patients. Recent report shows that vitamin K2 (menaquinone-4) possesses potent antioxidative properties, and was found to significantly inhibit rotenone-induced p38 activation, ROS production and caspase-1 activity and subsequently, restored mitochondrial membrane potential, showing its potential in the treatment of neuroinflammation-induced PD [263]. Similarly, vitamin K2 was found effective to modulate bax and caspase-3 activation in PC12 mouse neuroblastoma cells, protecting it from 6-OHDA induced apoptosis [264]. Notably, one recent report has shown that low levels of vitamin K2 in PD patients are associated with dysregulated inflammatory responses and cascade coagulation signals [265]. Deficiency of vitamin B was also found to be associated with neurological disorders like beriberi, and polyneuropathy [266]. Similarly, folate deficiency was found to be associated with cognitive impairment and progressive dementia in older women [267]. Also, high intake of B6, B9 and B12 decreases the rate of atrophy in the brain region linked with the cognitive decline in AD [268]. Further, more constructive studies will be required to prove the potential link of gut microbiota produced vitamins in neuroprotection.

**Antioxidative and anti-inflammatory effects of probiotics**

Free radicals in the form of ROS are byproducts of normal cellular metabolic processes. Free radicals are potentially able to damage the genetic material, enzymes inactivation, depolymerization of complex carbohydrates and lipid peroxidation. This vandalization of intracellular molecules leads to the cell death. To balance the free radicals, the body have specific antioxidants such as glutathione [269]. Some products also started to flow in pharmaceutical markets to tackle oxidative stress such as ferulic acid (FA) due to its antioxidative and anti-inflammatory properties. It helps to proliferate neuronal stem cells by enhancing the production of BDNF and nerve growth factor (NGF) and some neuropeptides having anti-inflammatory properties [270,271]. In 2017, Westfall et al. reported that FA is also produced by probiotic bacteria such as Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum NCIMB 5221 and Bifidum animalis in large quantity by bacterial FA esterase enzymes [272]. Due to its therapeutic effect, it is gaining attention...
for its use in AD treatment, pre-treatment with FA has been shown to reduce the Aβ fibrils and to treat the neuroinflammation in AD mice [273]. FA-producing probiotic bacteria inhibits the formation and aggregation of beta-amyloid fibrils through scavenging ROS.

Other probiotic bacterial protein, sirtuin-1 (SIRT1) protein deacetylase has been shown to have antioxidant properties. This protein regulates the genes of antioxidant pathways of host and has been documented to have neuroprotective effects. Recent research probed the capability of a formulation of probiotic bacteria named SLAB51 (Streptococcus thermophilus, Lactobacillus acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus, L. brevis, Bifidobacterium longum, B. breve, B. infantis) to relieve oxidative stress and discovered the molecular mechanism of its effects [274]. In the treated transgenic 3xTg-AD mice, the expression and activity of SIRT1 protein in the brain were observed to be retrieved and the formation of Aβ peptide was shown decreased. However, in untreated AD mice, the expression of SIRT1 was found to be substantially decreased. Moreover, the enhanced activity of SIRT1 reduces the p53 protein acetylation and improves the survival of stressed cells by repressing apoptotic pathways. Other studies also showed that probiotic supplements activate the SIRT1 pathway and provoke antioxidative effects. SLAB51 also enhances the activity of GPx and catalase antioxidant enzymes to alleviate oxidative stress-causing impairments. Similar findings were also observed in humans. The concentration of SIRT1 in the brains of AD patients was found significantly reduced which is closely associated with the accumulation of amyloid-β and tau in the cerebral cortex of persons with AD [275]. An improved level of SIRT1 has been reported in a human study supplemented with Lactobacillus casei 01, a probiotic strain [276].

There is a very fragile relationship between gut microbiota and host immune cells. Immune cells are specialized to peculiarly differentiate the host friendly bacteria from pathogenic bacteria. If this relationship hurts, it can lead to unnecessary immune responses, prompting chronic inflammation [277]. This differentiation is started by intestinal epithelial cells who are responsible for producing the educated macrophage phenotype based on bacterial cell surface antigens such as LPS, peptidoglycan and flagellin. When epithelial cells become vulnerable to pathogenic attack, the antigens translocate into vasculature and in response, proinflammatory cytokines such as IL (interleukin)-1, IL-6, and tumor necrosis factor-alpha (TNF-α) are produced, which leads to septic shock and inflammation in the gut and brain. Some bacterial toxins can also cross the BBB [269,278]. To gaze at the role of microbiota in amyloidosis, an investigation was conducted through assessing the pro-(CXCL2, CXCL10, IL-1β, IL-6, IL-18, IL-8, inflammasome complex NLRP3, TNF-α) and anti-inflammatory (IL-4, IL-10, IL-13) cytokine activity of several gut microbiota taxa in cognitively impaired patients and it was observed that the number of Escherichia/Shigella increases and Eubacterium rectale decreases significantly correlated with changes in concentration of pro- and anti-inflammatory cytokines in cognitively impaired and amyloid positive patients. In concert, an increased level of IL-6, CXCL2, NLRP3, and IL-1β and a decreased level of IL-10 was observed in AD patients. This study suggests that gut microbiota could initiate, worsen or alleviate peripheral inflammation in neurological diseases [279].

**In silico strategies to advance the gut-brain research**

With the advancement of technology, knowledge about the brain is increasing exponentially. The neuroscientists have generated plenty of data from molecular biology, molecular genetics, brain imaging, and other new technologies, and have a significant interest in sharing the neuroscience data for various analysis. Neuroimaging is also very helpful in predicting and detecting NDDs and mental disorders. In the interest of neuroscience data collection and analysis, various bioinformatics tools are being developed for the further development of devices based on brain functions. To date, researchers have a rudimentary knowledge of molecular pathways involved in neurodegeneration due to various stress conditions. The integrated databases will be helpful to collect the different types of data related to neurodegeneration diseases from publicly available sources (Table 2).

### Table 2

Overview of currently active databases related to neurological data.

| Database | Web address | Data type | Reference(s) |
|----------|-------------|-----------|--------------|
| PDGene | http://www.pdgene.org/ | Meta-analysis of genome-wide association studies (GWAS) | [304] |
| MDSGene | http://www.mdsgene.org/ | Genetic mutations, movement disorder genes related to PD | [305] |
| Alzforum | https://www.alzforum.org/ | Repository of variants in genes linked to AD | [306] |
| AlzGene | http://www.alzgene.org/ | Systematic meta-analyses of AD | [307] |
| Neuroinformatics Database (NIDB) | https://www.nitr.org/projects/nidb/ | Imaging | [308] |
| Neuroscience Information Framework (NIF) | https://neuinfo.org/ | Metadata (imaging, genes, omics, function, grants, protocols etc.) | [309] |
| BrainMaps | http://brainmaps.org/ | Brain structure and function | [310] |
| Hippocampus Portal | http://www.hippocampus.org/php/index.php | Morphology, molecular marker, membrane biophysics and synaptic physiology | [311] |
| NeuroElectro | https://neuroelectro.org/ | Electrophysiological properties | [312] |
| NeuroMorpho | http://neuromorpho.org/index.jsp | Neuromorphology and metadata | [313] |
| NeuronDB | https://senselab.med.yale.edu/NeuronDB/ | Voltage gated conductances, neurotransmitter receptors, and neurotransmitter substances | [313] |
| Collaborative Research in Computational Neuroscience (CRCNS) | http://crcns.org/ | Electrophysiology and behavioral data | [314] |
| Neuroimaging Tools and Resources Collaboratory (NITRC) | https://www.nitr.org/ | Neuroimaging, imaging genomics software tools, data, and computational resources | [315] |
| BigBrain | https://bigbrainproject.org/ | Ultrahigh-Resolution 3D Human Brain Model | [316] |
| Brain Transcriptome database (BrainTx) | http://www.cdtb.brain.riken.jp | Gene expression | [317] |
| Marmoset Gene Atlas | https://gene-atlas.brainminds.riken.jp/ | Gene expression | [318] |
| Allen Brain Map | https://portal.brain-map.org/ | Metadata (gene expression, imaging toolkits etc.) | [319] |
| BrainCloud | https://www.libd.org/brain-cloud/ | Gene expression | [320] |
| M²IA | http://m2ia.met-bioinformatics.cn/ | Microbiome and metabolome integrative analysis | [283] |
| Microbiota-Active Substance Interaction Database (MASI) | http://www.aiddlab.com/MASI/ | Effect of bioactive compounds on microbiota and vice versa | [284] |
The comprehensive knowledge of microbiome and their importance in human health is increasing at a fast pace with the aggrandizement of high throughput technologies. Microbiota interacts with the host metabolites and converts them to secondary metabolites. Gut microbiota also produces their metabolites which play very important role in human health. Comprehending the interaction of metabolites and gut microbiota, it is important to know the function of microbiota in health and disease status and to develop natural therapies [280]. In the recent past, it has been proved that gut bacteria can alter CNS physiology and dysbiosis could be a potential factor in neuroinflammation [281]. In 2019, Lu and Claud reported that initial colonization and microbiota development affect brain development in preterm infants [282]. To manage and facilitate this exponentially increasing information, microbiota databases are being developed for in-depth understanding of the role of microbiota in human health. To establish the correlation between microbiota and metabolites, new pipelines are being developed such as M^3IA, an automated microbiome and metabolome integrative analysis pipeline [283]. Other microbiota databases provide useful information about disease-associated microbes, modulation of drugs by microbiota, the effect of diet on gut microbes. To distribute the knowledge about the alteration of active substances such as therapeutic drugs, dietary components, herbal products, probiotics and environmental chemicals by microbiota and alteration of microbiota by active substances, Microbiota–Active Substance Interactions (MASI) database is developed [284]. These databases will be very helpful to establish the correlation between bacterial metabolites and neuronal health and pathogenesis. It has been reported that in clinical trials, the outcome of L-dopa treatment for PD varies between the recruiting subjects. This variation is because of their microbiota. L-dopa is metabolized by Tyrosine decarboxylase (TDC) and dopamine dehydroxylase (Dadh) of different gut bacterial species namely Enterococcus faecalis and Eggerthella lenta A2 [285]. For the inactivation of bacterial L-dopa decarboxylase, a drug, (S)-α-fluoromethyltyrosine (AFMT) was discovered. The combination of L-dopa and AFMT is being used for Parkinson’s treatment. Zhuang et al. showed that gut microbiota is altered in patients with AD compared to healthy individuals at taxonomic levels, such as Bacteroides, Actinobacteria, Ruminococcus, Lachnospiraceae, and Selenomonadales [286]. Metagenomic data/16S RNA sequencing data support firm association between dysbiosis and AD. Bacterial products such as LPS and bacterial enzymes mediating the production of harmful metabolites limit. Bioinformatic tools are the need of the hour, which could potentiate the designing of such drugs that can target the specific bacterial enzymes mediating the production of harmful metabolites. Nonprotective and neurodegenerative roles of gut microbial metabolites are continued to be uncovered, providing opportunities to develop novel therapeutic modalities.

Funding

Authors received no specific funding for this work. Department of Applied Physics, Aalto University has supported the APC or open access fee.

Consent for publication

All authors have read the final version of the manuscript and have given their consent for publication.

CRediT authorship contribution statement

Shruti Shandilya: Conceptualization, Writing – original draft, Writing – review & editing, Artwork & schemes, Visualization. Sandeep Kumar: Writing – original draft, Writing – review & editing, Software. Niraj Kumar Jha: Formal analysis, Editing, Artwork & schemes. Kavindra Kumar Kesari: Supervision, Writing – review & editing, Validation. Janne Ruokolainen: Supervision, Validation, Data curation, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Rao M, Gershon MD. Enteric nervous system development: what could possibly go wrong? Nat Rev Neurosci 2018;19(9):552–65. doi: https://doi.org/10.1038/s41583-018-0041-0.
[2] Morais LH, Schreiber HL, Mazmanian SK. The gut microbiota–brain axis in behaviour and brain disorders. Nat Rev Microbiol 2021;19(4):241–55. doi: https://doi.org/10.1038/s41579-020-00460-0.
[3] Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell 2016;164(3):337–40. doi: https://doi.org/10.1016/j.cell.2016.01.013.
[4] Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015;148(1):30–6. doi: https://doi.org/10.1053/j.gastro.2014.10.042.
[5] Zheng D, Liwinski T, Elina E. Interaction between microbiota and immunity in health and disease. Cell Res 2020;30(6):492–506. doi: https://doi.org/10.1038/s41422-020-0332-7.
[6] Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest 2019;129(4):4050–7. doi: https://doi.org/10.1172/jci129196.
[7] Collins J, Borodjevic R, Verdu EF, Huizenga JD, Ratcliffe EM. Intestinal microbiota influence the early postnatal development of the enteric nervous system. Neurogastroenterol Motil 2014;26(1):98–107. doi: https://doi.org/10.1111/nmo.2013.26.issue-1.
[8] David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505(7484):559–63. doi: https://doi.org/10.1038/nature12820.
[9] Vich Vila A, Collivi V, Sanna S, Sinha T, Inihann F, Bourgonje AR, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun 2020;11(1). doi: https://doi.org/10.1038/s41467-019-14177-2.
[10] de la Cuesta-Zuluaga J, Kelley ST, Chen Y, Escobar JS, Mueller NT, Ley RE, et al. Age- and Sex-Dependent Patterns of Gut Microbial Diversity in Human Adults. mSystems 2019;4. doi: https://doi.org/10.1128/msystems.00261-19.
[11] Catanazzo JR, Strauss JD, Bielecka A, Porto AF, Lobo FM, Urban A, et al. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of
Parkinson's Disease. Front Aging Neurosci 2019;8:94. doi: https://doi.org/10.3389/fnagi.2019.00094.

[152] Weiner's Half, Hawthorn J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter L et al. Infarction-meditated Disease and Parkinson's Disease. A Nationwide Swedish Cohort Study. Inflamm Bowel Dis 2019;25:111–23. https://doi.org/10.1093/ibd/izy190.

[153] Mathieu-Dono, panorama Tyler, Vossin Aurore, Pentlin Anna-Majaa, Ramet Laura, Fabian Ahmed M, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1−/− mice. Nature 2019;571(7766):565–9. doi: https://doi.org/10.1038/s41586-019-1405-y.

[154] Beger Helmut R, Hildesheim LS, Goozmann SP, Sajabrah M, Goess F, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients. Genome Med 2017;9:11. doi: https://doi.org/10.1186/s13073-017-0124-y.

[155] Belzal VM, Bessman J, Tumblobo PG, Balukis EP, Discovery and inhibition of an intercessly gut bacterial pathway for Lvedopa metabolism. Science (80-20) 2019;364:1055. https://doi.org/10.1126/science.aee6323.

[156] van Kessel SF, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun 2019;10:1–11. doi: https://doi.org/10.1038/s41467-019-08294-y.

[157] Ohta Shigeo. Molecular hydrogen as a preventive and therapeutic medical gas. Int J Mol Sci 2015;16:24775–84. doi: https://doi.org/10.3390/ijms160924775.

[158] Kigerl KA, Hall JCE, Wang L, Mo X, Yu Z, Popovich GC, Gut dysbiotics recovery after spinal cord injury. J Exp Med 2016;213:2603–20. doi: https://doi.org/10.1084/jem.20161345.
Cassani E, Privitera G, Pezzoli G, ... Labarre A, Guitard E, Tossing G, Bareke E, Labrecque M, Tétreault M, et al. Rezaei Asl Zahra, Sepehri Gholamreza, Salami Mahmoud. Probiotic treatment ... microorganisms. J Immunoass Immunochem 2021;42:190063. doi: https://doi.org/10.1056/jimm.2021.031917.

Cheon M-J, Lim S-M, Lee N-K, Paik H-D. Probiotic Properties and Neuroprotective Effects of Lactobacillus buchneri KI200793 Isolated from Korean Fermented Foods. Int J Mol Sci 2020;21:1227. doi: 10.3390/ijms21041227.

Cecarini Valentina, Bonfili Laura, Gogoi Olee, Lawrence Solomon, Venanzi Franco M, Azevedo Vasco, et al. Neuroprotective effects of pS2 (QSTM1)-engineered lactic acid bacteria in Alzheimer’s Disease: A pre-clinical study. Aging (Albany NY) 2020;12(16):5959–6020.

Labarre A, Guitard T, Ermou I, Barazzone M, Tétard A, et al. Use of probiotics for the biochemical, and histological study. J Immunoass Immunochem 2021;42:190063. doi: https://doi.org/10.1056/jimm.2021.031917.

Sun J, Xu J, Yang B, Chen K, Kong Y, Fang N, et al. Effect of Clostridium butyricum against Microglia-Mediated Neuroinflammation in Alzheimer’s Disease. Microbes Regul Microbiota and Bacteroidetes Butyrate: A Gut Dysbiosis and Amyloid Pathology in Alzheimer’s Disease. J Alzheimer’s Dis 2020;78(2):683–97. doi: https://doi.org/10.3233/JAD-200136.

Moon J, Stratton Issac, Stone James M, Jones Edward G. Internet-enabled high-resolution brain mapping and virtual microscopy. Neuroimage 2007;35(1):9–15. doi: https://doi.org/10.1016/j.neuroimage.2006.11.053.

Dwyer DW, White CM, Rees CI, Komendantov AO, Hamilton DJ, Ascoli GA. Hippocampome.org: A knowledge base of neuron types in the rodent hippocampus. Elife 2015;4. https://doi.org/10.7554/eLife.09960.

Tripathy S, Savitskaya J, Urban NN, Gerkin RC. NeuroElectro: A window to the world’s neuron electrophysiology data. Front Neuroinform 2014;8. doi: https://doi.org/10.3389/fninf.2014.00040.

Ascoli GA, Donohue DE, Halavi M. NeuroMorpho.Org: A central resource for neuronal morphologies. J Neurosci 2007;27:9247–51. doi: 10.1523/JNEUROSCI.0552-07.2007.

Teeters JH, Harris KD, Millman KJ, Olshausen BA, Sommer FT. Data sharing for computational neuroscience. Neuroinformatics, vol. 6, Springer; 2008, p. 47–55. https://doi.org/10.1007/978-1-59745-520-6_19.

Kennedy DN, Haseglove C, Riehl J, Preuss N, Bucigrossi R. The Three NITRCs: A Guide to Neuroimaging Neuroinformatics Resources. Neuroinformatics. 2015 Jul;13(3):383–6. doi: https://doi.org/10.1007/s12021-015-9363-8.

Shimogori Tomomi, Abe Ayumi, Go Yashiro, Hashikawa Totsu, Kishi Noriyuki, Kikuchi Satomi S, et al. Digital gene atlas of neonate common marmoset brain. Neurosci Res 2018;128:1–13. doi:https://doi.org/10.1016/j.neures.2017.10.009.

Sakou Akira, Sekine Yukiko, Saruta Chihiro, Nishibe Hirozumi, Morita Noriyuki, Sato Yumi, et al. Cerebellar development transcriptome database (CĐT-DB): Profiling of spatio-temporal gene expression during the postnatal development of mouse cerebellum. Neuronal Networks 2008;21(8):1056–69. doi: https://doi.org/10.1016/j.neunet.2008.05.004.

Shimogori Tomomi, Abe Ayumi, Go Yashiro, Hashikawa Totsu, Kishi Noriyuki, Kikuchi Satomi S, et al. Digital gene atlas of neonate common marmoset brain. Neuronal Networks 2008;21(8):1056–69. doi: https://doi.org/10.1016/j.neunet.2008.05.004.

Lein Ed S, Hawrylycz Michael J, Ao Nancy, Ayres Mikael, Bensinger Amy, et al. Neuroinformatics database (NiDB) - A modular, portable database for the storage, analysis, and sharing of neuroimaging data. Neuroinformatics 2013;11(4):495–505. doi: 10.1007/s12021-013-9194-3.

Gardner Daniel, Aki Huda, Ascoli Giorgio A, Bowden Douglass M, Bug William, Donohue Duncan E, et al. The neuroscience information framework: A data and knowledge environment for neuroscience. Neuroinformatics 2008;6(3):149–60. doi: https://doi.org/10.1007/s12021-008-9024-7.

Mukula Shawn, Trouss Isac, Stone James M, Jones Edward G. Internet-enabled high-resolution brain mapping and virtual microscopy. Neuroimage 2007;35(1):9–15. doi: https://doi.org/10.1016/j.neuroimage.2006.11.053.

Dwyer DW, White CM, Rees CI, Komendantov AO, Hamilton DJ, Ascoli GA. Hippocampome.org: A knowledge base of neuron types in the rodent hippocampus. Elife 2015;4. https://doi.org/10.7554/eLife.09960.

Tripathy S, Savitskaya J, Urban NN, Gerkin RC. NeuroElectro: A window to the world’s neuron electrophysiology data. Front Neuroinform 2014;8. doi: https://doi.org/10.3389/fninf.2014.00040.

Ascoli GA, Donohue DE, Halavi M. NeuroMorpho.Org: A central resource for neuronal morphologies. J Neurosci 2007;27:9247–51. doi: 10.1523/JNEUROSCI.0552-07.2007.

Teeters JH, Harris KD, Millman KJ, Olshausen BA, Sommer FT. Data sharing for computational neuroscience. Neuroinformatics, vol. 6, Springer; 2008, p. 47–55. https://doi.org/10.1007/978-1-59745-520-6_19.

Kennedy DN, Haseglove C, Riehl J, Preuss N, Bucigrossi R. The Three NITRCs: A Guide to Neuroimaging Neuroinformatics Resources. Neuroinformatics. 2015 Jul;13(3):383–6. doi: https://doi.org/10.1007/s12021-015-9363-8.

PMID: 27006757; PMCID: PMC4470578.

Amunts K, Legape K, Borgeat L, Möbigger H, Dickscheid T, Rausseau M-E, et al. BigBrain: An ultra-highres 3D human brain model. Science (80-). 2013;340(6139):1472–5. doi: https://doi.org/10.1126/science.1233581.

Sato Akira, Sekine Yukiko, Saruta Chihiro, Nishibe Hirozumi, Morita Noriyuki, Sato Yumi, et al. Cerebellar development transcriptome database (CĐT-DB): Profiling of spatio-temporal gene expression during the postnatal development of mouse cerebellum. Neuronal Networks 2008;21(8):1056–69. doi: https://doi.org/10.1016/j.neunet.2008.05.004.

Shimogori Tomomi, Abe Ayumi, Go Yashiro, Hashikawa Totsu, Kishi Noriyuki, Kikuchi Satomi S, et al. Digital gene atlas of neonate common marmoset brain. Neurosci Res 2018;128:1–13. doi: https://doi.org/10.1016/j.neures.2017.10.009.

Lein Ed S, Hawrylycz Michael J, Ao Nancy, Ayres Mikael, Bensinger Amy, Bernard Amy, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007;445(7124):519–23. doi: https://doi.org/10.1038/nature05453.

Colantuoni Carlo, Lipska Barbara K, Ye Tianzhang, Hyde Thomas M, Tao Ran, Leek Jeffrey T, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011;478(7370):519–23. doi: https://doi.org/10.1038/nature10524.
Sandeep Kumar is currently working with the clinical research company as a data analyst. He completed his Ph.D. degree from Animal Biochemistry Department, National Dairy Research Institute (NDRI), India. His work was focused on the commensal bacteria and acquired resistance by them. He has expertise in biochemical techniques and bioinformatics data analysis. He has published many research articles in recognized peer review journals.

Dr. Niraj Kumar Jha is currently working as an Assistant Professor in the Department of Biotechnology at Sharda University, Greater Noida, India. He is a former Assistant Professor of the faculty of Biotechnology, Noida Institute of Engineering and Technology (NIET), affiliated with Abdul Kalam Technical University (AKTU), India. He holds a doctorate in Biotechnology from Delhi Technological University (DTU) and a postgraduate degree in Biotechnology from Vellore Institute of Technology, TN, India. During the doctorate program, DBT granted him a fellowship as a financial boost to accomplish research work. He has published over 90 quality scholarly work and 5 book chapters in prestigious international journals and presented over 10 research papers in top national and international conferences. He is an editorial board member of various high repute international journals and assisted significantly in reviewing articles of many international journals such as Scientific reports, Life sciences, European journal of pharmaceutical sciences and Journal of food biochemistry. Currently, he is working on cell ultrastructure study with micro & macro spectroscopic techniques. He has developed various methods for cell culture and animal exposure to radiations and therapeutic measures. His study explores the medicinal applications of plant derived bioactive compounds and nanoparticles for disease treatment. He has published over 85 scientific papers in scientific journals, 22 book chapters, 5 books and presented over 25 papers at national and international scientific meetings. His Hirsch index (h-index) as of August 2021 is 29 on Google Scholar, 24 on Scopus. He has received four times young scientist award. His research interest is focus on neurobiology, radiation and cancer biology and therapeutic research.

S. Shandilya, S. Kumar, N. Kumar Jha et al. Journal of Advanced Research 38 (2022) 223–244

Kavindra Kesari is currently working as Senior Researcher in the Department of Applied Physics at the Aalto University, Espoo, Finland. He obtained Doctoral, Master, and Bachelor degrees in Biotechnology from India. He served as an Assistant Professor position at Jaipur National University, Jaipur, India. He obtained his first Postdoctoral research from University of Eastern Finland, Kuopio, Finland. Currently, he is working on cell ultrastructure study with micro & macro spectroscopic techniques. He has developed various methods for cell culture and animal exposure to radiations and therapeutic measures. His study explores the medicinal applications of plant derived bioactive compounds and nanoparticles for disease treatment. He has published over 85 scientific papers in scientific journals, 22 book chapters, 5 books and presented over 25 papers at national and international scientific meetings. His Hirsch index (h-index) as of August 2021 is 29 on Google Scholar, 24 on Scopus. He has received four times young scientist award. His research interest is focus on neurobiology, radiation and cancer biology and therapeutic research.

Janne Ruokolainen is a Professor in the Department of Applied Physics, Aalto University, Espoo, Finland. He gained his PhD (Tech) in Materials Physics from Helsinki University of Technology and Docentship in polymer physics and soft materials microscopy. His current research activities focus the characterization of molecular bioactive compounds extracted from plant species in neurodegenerative disease treatment. He has published over 250 scientific papers in peer reviewed and refereed journals. Since 1995, he has gained high bibliometric factor, where H-index 62 (google scholar). His awards and research honours include invitation to the Alfred Nobel Symposium (2005), Young Scientist Award by Foundation of Technology (2002), Prize for the best PhD Thesis in the field of technical sciences by Tekniikan Akateemisten Liitto and Tekniska Föreningen in Finland (TEK/TFiF) (2001), IUPAC Prize for Young Chemists – Honourable Mention Award (2001).